SOUTH SAN FRANCISCO, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation in two investor conferences during the month of February.
The 18th Annual BIO CEO & Investor Conference
On Tuesday, February 9, 2016, Christopher J. Molineaux, Ph.D., Senior Vice President of Development, will present a corporate update at 2:30 pm EST. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City.
Leerink Global Healthcare Conference
On Wednesday, February 10, 2016, Dr. Molineaux will participate in a fireside chat to discuss recent corporate developments at the Leerink Global Healthcare Conference being held in New York City at 1:50 p.m. EST.
These presentations will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
CONTACT: Contact: Jennifer McNealey ir@Calithera.com 650-870-1071